Find Finafloxacin manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

API Suppliers

API Suppliers

0

USDMF

US DMFs Filed

0

CEP/COS

CEP/COS Certifications

0

JDMF

JDMFs Filed

0

EU WC

EU WC

0

KDMF

KDMF

0

VMF

NDC API

0

Listed Suppliers

Other Suppliers

API REF. PRICE (USD/KG)

$
$ 0

MARKET PLACE

0

FDF

0INTERMEDIATES

FINISHED DOSAGE FORMULATIONS

0

Europe

Europe

0

Canada

Canada

0

Australia

Australia

0

South Africa

South Africa

0

Listed Dossiers

Listed Dossiers

0 DRUGS IN DEVELOPMENT

FDF Dossiers

DRUG PRODUCT COMPOSITIONS

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

PATENTS & EXCLUSIVITIES

0

US Exclusivities

DIGITAL CONTENT

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

GLOBAL SALES INFORMATION

US Medicaid

NA

Annual Reports

NA

Finished Drug Prices

NA

0RELATED EXCIPIENT COMPANIES

0EXCIPIENTS BY APPLICATIONS

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 209342-40-5, Xtoro, Finafloxacin [inn], D26osn9q4r, Al-60371, Chebi:85176
Molecular Formula
C20H19FN4O4
Molecular Weight
398.4  g/mol
InChI Key
FYMHQCNFKNMJAV-HOTGVXAUSA-N
FDA UNII
D26OSN9Q4R

Finafloxacin
Finafloxacin is a fluoroquinolone antibiotic indicated in the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus. Finafloxacin is marketed by Novartis under the brand Xtoro, and was approved by the FDA in December 2014.
Finafloxacin is a Quinolone Antimicrobial.
1 2D Structure

Finafloxacin

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
7-[(4aS,7aS)-3,4,4a,5,7,7a-hexahydro-2H-pyrrolo[3,4-b][1,4]oxazin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic acid
2.1.2 InChI
InChI=1S/C20H19FN4O4/c21-14-5-11-17(25(10-1-2-10)7-13(19(11)26)20(27)28)12(6-22)18(14)24-8-15-16(9-24)29-4-3-23-15/h5,7,10,15-16,23H,1-4,8-9H2,(H,27,28)/t15-,16-/m0/s1
2.1.3 InChI Key
FYMHQCNFKNMJAV-HOTGVXAUSA-N
2.1.4 Canonical SMILES
C1CC1N2C=C(C(=O)C3=CC(=C(C(=C32)C#N)N4CC5C(C4)OCCN5)F)C(=O)O
2.1.5 Isomeric SMILES
C1CC1N2C=C(C(=O)C3=CC(=C(C(=C32)C#N)N4C[C@H]5[C@H](C4)OCCN5)F)C(=O)O
2.2 Other Identifiers
2.2.1 UNII
D26OSN9Q4R
2.3 Synonyms
2.3.1 MeSH Synonyms

1. 3-quinolinecarboxylic Acid, 8-cyano-1-cyclopropyl-6-fluoro-7-((4as,7as)-hexahydropyrrolo(3,4-b)-1,4-oxazin-6(2h)-yl)-1,4-dihydro-4-oxo-

2. Xtoro

2.3.2 Depositor-Supplied Synonyms

1. 209342-40-5

2. Xtoro

3. Finafloxacin [inn]

4. D26osn9q4r

5. Al-60371

6. Chebi:85176

7. Finafloxacin (inn)

8. 8-cyano-1-cyclopropyl-6-fluoro-7-((4as,7as)-hexahydropyrrolo[3,4-b][1,4]oxazin-6(2h)-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid

9. Bay35-3377

10. (-)-8-cyano-1-cyclopropyl-6-fluoro-7-((4as,7as)-hexahydropyrrolo(3,4-b)-1,4-oxazin-6(2h)-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid

11. 7-[(4as,7as)-3,4,4a,5,7,7a-hexahydro-2h-pyrrolo[3,4-b][1,4]oxazin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic Acid

12. Gastrochinolon

13. Gastroquinolone

14. 8-cyano-1-cyclopropyl-6-fluoro-7-[(4as,7as)-hexahydropyrrolo[3,4-b][1,4]oxazin-6(2h)-yl]-4-oxo-1,4-dihydroquinoline-3-carboxylic Acid

15. Xtoro (tn)

16. Finafloxacin [mi]

17. Unii-d26osn9q4r

18. Finafloxacin [who-dd]

19. Schembl1002869

20. Chembl1908370

21. Gtpl10809

22. Dtxsid10175096

23. Finafloxacin [orange Book]

24. Bcp23882

25. Zinc3985346

26. Al60371

27. Cs-5557

28. Db09047

29. Ncgc00510315-02

30. (-)-8-cyano-1-cyclopropyl-6-fluoro-7-((4as,7as)-hexahydropyrrolo(3,4-b)-1,4-oxazin-6(2h)-yl)-4-oxo-1

31. Ac-29291

32. Hy-13451

33. D10575

34. Q21011229

35. 3-quinolinecarboxylic Acid,8-cyano-1-cyclopropyl-6-fluoro-7-[(4as,7as)-hexahydropyrrolo[3,4-b]-1,4-oxazin-6(2h)-yl]-1,4-dihydro-4-oxo-

36. 7-[(4as,7as)-3,4,4a,5,7,7a-hexahydro-2h-pyrrolo[3,4-b][1,4]oxazin-6-yl]-8-cyano-1-cyclopropyl-6-fluoro-4-oxoquinoline-3-carboxylic Acid,hydrochloride

37. 8-cyano-1-cyclopropyl-6-fluoro-7-((1s,6s)-2-oxa-5,8-diazabicyclo[4.3.0]non-8-yl)-1,4-dihydro-4-oxo-3-quinolinecarboxylic Acid

38. 8-cyano-1-cyclopropyl-6-fluoro-7-[(4as,7as)-hexahydropyrrolo[3,4-b][1,4]oxazin-6(2h)-yl]-4-oxo-1,4-dihydro-3-quinolinecarboxylic Acid

2.4 Create Date
2006-10-26
3 Chemical and Physical Properties
Molecular Weight 398.4 g/mol
Molecular Formula C20H19FN4O4
XLogP3-0.7
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count9
Rotatable Bond Count3
Exact Mass398.13903326 g/mol
Monoisotopic Mass398.13903326 g/mol
Topological Polar Surface Area106 Ų
Heavy Atom Count29
Formal Charge0
Complexity806
Isotope Atom Count0
Defined Atom Stereocenter Count2
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count1
4 Drug and Medication Information
4.1 Drug Indication

Finafloxacin is indicated for the treatment of acute otitis externa (AOE) with or without an otowick, caused by susceptible strains of Pseudomonas aeruginosa and Staphylococcus aureus in patients age 1 year and older.


FDA Label


5 Pharmacology and Biochemistry
5.1 MeSH Pharmacological Classification

Anti-Bacterial Agents

Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)


Anti-Infective Agents, Urinary

Substances capable of killing agents causing urinary tract infections or of preventing them from spreading. (See all compounds classified as Anti-Infective Agents, Urinary.)


Topoisomerase II Inhibitors

Compounds that inhibit the activity of DNA TOPOISOMERASE II. Included in this category are a variety of ANTINEOPLASTIC AGENTS which target the eukaryotic form of topoisomerase II and ANTIBACTERIAL AGENTS which target the prokaryotic form of topoisomerase II. (See all compounds classified as Topoisomerase II Inhibitors.)


5.2 FDA Pharmacological Classification
5.2.1 Active Moiety
FINAFLOXACIN
5.2.2 FDA UNII
D26OSN9Q4R
5.2.3 Pharmacological Classes
Chemical Structure [CS] - Quinolones
5.3 Mechanism of Action

Finafloxacin is a fluoroquinolone antibiotic, which selectively inhibit bacterial type II topoisomerase enzymes, DNA gyrase and topoisomerase IV, which are required for bacterial DNA replication, transcription, repair and recombination.


Digital Content read-more

Create Content with PharmaCompass, ask us

DATA COMPILATION #PharmaFlow

read-more
read-more

NEWS #PharmaBuzz

read-more
read-more

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Finafloxacin Manufacturers

A Finafloxacin manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Finafloxacin, including repackagers and relabelers. The FDA regulates Finafloxacin manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Finafloxacin API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

Finafloxacin Suppliers

A Finafloxacin supplier is an individual or a company that provides Finafloxacin active pharmaceutical ingredient (API) or Finafloxacin finished formulations upon request. The Finafloxacin suppliers may include Finafloxacin API manufacturers, exporters, distributors and traders.

Finafloxacin NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Finafloxacin as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Finafloxacin API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Finafloxacin as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Finafloxacin and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Finafloxacin NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Finafloxacin suppliers with NDC on PharmaCompass.

Finafloxacin GMP

Finafloxacin Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Finafloxacin GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Finafloxacin GMP manufacturer or Finafloxacin GMP API supplier for your needs.

Finafloxacin CoA

A Finafloxacin CoA (Certificate of Analysis) is a formal document that attests to Finafloxacin's compliance with Finafloxacin specifications and serves as a tool for batch-level quality control.

Finafloxacin CoA mostly includes findings from lab analyses of a specific batch. For each Finafloxacin CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Finafloxacin may be tested according to a variety of international standards, such as European Pharmacopoeia (Finafloxacin EP), Finafloxacin JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Finafloxacin USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty